XML 74 R67.htm IDEA: XBRL DOCUMENT
v3.25.1

Fair Value Measurements and Marketable Equity Securities - Additional Information (Detail) - USD ($) |  | 1 Months Ended | 3 Months Ended |
--- | --- | --- | --- | ---
Mar. 11, 2025 | Aug. 31, 2024 | Mar. 31, 2025 | Mar. 31, 2024 | Dec. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Contingent consideration classified as equity, fair value disclosure |  |  | $ 838,000 |  |
Aggregate proceeds from sale of marketable equity securities |  |  | 8,316,000 | $ 23,098,000 |
Marketable equity securities outstanding |  |  | $ 67,183,000 |  | $ 107,309,000
Investment In Recursion Pharmaceuticals Class A Common Stock [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Investment in equity securities at fair value sold number of shares |  |  | 737,466 | 1,725,902 |
Weighted average price per share of investment sold |  |  | $ 11.28 | $ 13.38 |
Aggregate proceeds from sale of marketable equity securities |  |  | $ 8,300,000 | $ 23,100,000 |
Deep 6 Acquisition [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Number of held back shares in connection with business acquisition | 17,372 |  |  |  |
Fair Value, Inputs, Level 1 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Contingent consideration classified as equity, fair value disclosure |  |  | 838,000 |  |
Fair Value, Inputs, Level 2 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Contingent consideration classified as equity, fair value disclosure |  |  | 0 |  |
Fair Value, Inputs, Level 3 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Contingent consideration classified as equity, fair value disclosure |  |  | 0 |  |
Gain or loss due to change in fair value for assets and liabilities measured at fair value using significant unobservable inputs (Level 3) |  |  | 0 |  |
Company recognized gain (loss) due change fair value of warrant liability |  |  |  | (800,000) |
Warrant [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Warrant issued |  |  | $ 100,000,000 |  |
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Class Of Warrant Share Issued |  |  | 9,218,800 |  |
Common stock purchase price |  | $ 18,400,000 |  |  |
Purchase of additional shares of common stock |  | 3,500,000 |  |  |
Purchase of additional shares of common stock value |  | $ 17,700,000 |  |  |
Outstanding common stock percentage |  | 20.00% |  |  |
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Class of Warrant or Right, Exercise Price of Warrants or Rights |  |  | $ 1.5 |  |
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Class of Warrant or Right, Exercise Price of Warrants or Rights |  |  | $ 2.5 |  |
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Class Of Warrant Excisable At Cash |  |  | 4,609,400 |  |
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Class Of Warrant Excisable At Cash |  |  | 4,609,400 |  |
Contingent Consideration [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Contingent consideration classified as equity, fair value disclosure |  |  | $ 800,000 |  |
Contingent Consideration [Member] | Fair Value, Inputs, Level 3 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Company recognized gain (loss) due change fair value of warrant liability |  |  |  | $ (200,000) |
Contingent Consideration [Member] | Common Stock [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Contingent consideration arrangement of non voting common stock |  |  | 35,000 |  |
Contingent Consideration [Member] | Common Stock [Member] | Fair Value, Inputs, Level 1 [Member] |  |  |  |  |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |
Contingent consideration arrangement of non voting common stock |  |  | 35,000 |  |

X
- Definition Class of warrant excisable at cash. + References No definition available. + Details
Name: | tem_ClassOfWarrantExcisableAtCash
Namespace Prefix: | tem_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Class of warrant share issued. + References No definition available. + Details
Name: | tem_ClassOfWarrantShareIssued
Namespace Prefix: | tem_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Company recognized gain (loss) due change fair value of warrant liability. + References No definition available. + Details
Name: | tem_CompanyRecognizedGainLossDueChangeFairValueOfWarrantLiability
Namespace Prefix: | tem_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent consideration arrangement of non voting common stock. + References No definition available. + Details
Name: | tem_ContingentConsiderationArrangementOfNonVotingCommonStock
Namespace Prefix: | tem_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investment in equity securities at fair value sold number of shares. + References No definition available. + Details
Name: | tem_InvestmentInEquitySecuritiesAtFairValueSoldNumberOfShares
Namespace Prefix: | tem_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of held back shares in connection with business acquisition. + References No definition available. + Details
Name: | tem_NumberOfHeldBackSharesInConnectionWithBusinessAcquisition
Namespace Prefix: | tem_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of outstanding common stock. + References No definition available. + Details
Name: | tem_PercentageOfOutstandingCommonStock
Namespace Prefix: | tem_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrant issued. + References No definition available. + Details
Name: | tem_WarrantIssued
Namespace Prefix: | tem_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Weighted average price per share of investment sold. + References No definition available. + Details
Name: | tem_WeightedAveragePricePerShareOfInvestmentSold
Namespace Prefix: | tem_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value of contingent consideration in a business combination that is classified in shareholders' equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of gain (loss) recognized in income from asset and liability measured at fair value on recurring basis using unobservable input (level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to reacquire common stock during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsForRepurchaseOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockRepurchasedDuringPeriodShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockRepurchasedDuringPeriodValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=tem_InvestmentInRecursionPharmaceuticalsClassACommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tem_Deep6AcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | tem_AgreementTypeAxis=tem_CommercializationAndReferenceLaboratoryAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tem_PersonalisIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerDurationAxis=tem_PriorDecember312024Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerDurationAxis=tem_PriorDecember312025Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tem_ContingentConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |